Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedUpdated the page’s software/revision version indicator from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check22 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check51 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check65 days agoChange DetectedSite revision label updated from v3.4.2 to v3.4.3 in the page header/footer.SummaryDifference0.1%

- Check87 days agoChange DetectedRevision: v3.4.2 was applied, replacing the previous v3.4.1. No substantive study information or user-facing content was changed.SummaryDifference0.1%

- Check94 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1, which does not alter the study details, inclusion criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.